• 

  Phil’s Journal: When Alzheimer’s Trials Are Cancelled, Notifying Study Participants in the Most ‘Humane’ Way
• 

  FDA Gives Biogen Green Light to Relaunch Aducanumab Study on Trial Participants
• 

  Phil’s Journal: Seeking to Understand the Science Behind Biogen’s Alzheimer’s Drug
• 

  Phil’s Journal: Biogen Cancelled Promising Alzheimer’s Study; Now They’re Bringing It Back
• 

  Biogen Revives Aducanumab, Experimental Alzheimer’s Drug, to Submit for FDA Approval
• 

  Biogen Ends Late-Stage Alzheimer’s Trials, Crushing Hopes and Calling Amyloid Into Question

Previous45